Parabilis Medicines

PBLS · Nasdaq Filing snapshot

Parabilis Medicines is a clinical-stage biopharma developing medicines against historically 'undruggable' protein targets. Its lead candidate, zolucatetide, is the first-ever drug to directly target the β-catenin/TCF interaction in the Wnt signaling pathway — a driver of multiple cancers. The company has not generated revenue. Its $20.00 Nasdaq IPO raised about $670M gross, and insiders retain significant voting control through a dual-class (voting / non-voting) structure. Because the mechanism is novel, the filing names only a few direct competitors — developers of γ-secretase inhibitors: Merck KGaA (Ogsiveo, from SpringWorks) and Immunome (varegacestat).

Listed

Jun 10, 2026

Raised

$670M

Sector

Biotechnology · Oncology · Drug Discovery

Named rivals

3 in the S-1

Named in the S-1 3 named

Parabilis Medicines

PBLS · the filer

Merck KGaA

named 1×

SpringWorks Therapeutics

named 1×

Immunome

named 1×

“

The read

Pioneering a drug for the 'undruggable' β-catenin/TCF target in the Wnt pathway. Because zolucatetide is first-of-its-kind, the filing names only a few indirect rivals in the adjacent γ-secretase field — Merck KGaA's Ogsiveo, SpringWorks and Immunome. A $670M raise on a novel mechanism; no revenue yet.

Want the full picture on Parabilis Medicines?

Request the deep Exposure Report — share-of-presence, a 90-day signal timeline, and the white space these 3 rivals leave open. We build it within 48 hours.

Request full coverage